Full Answer
What is the target price for 89Bio stock?
Their forecasts range from $33.00 to $95.00. On average, they anticipate 89bio's share price to reach $55.88 in the next year. This suggests a possible upside of 457.6% from the stock's current price. View analysts' price targets for 89bio or view top-rated stocks among Wall Street analysts. Who are 89bio's key executives?
How much of 89Bio's stock is owned by insiders?
In the past three months, 89bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $195,790.00 in company stock. 12.70% of the stock of 89bio is held by insiders.
What does 89Bio do?
Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
How many shares did 89Bio’s director buy for $10 million?
The company’s Director purchased 2,816,900 shares worth $10 million. 89bio, Inc. ( NYSE:ETNB) is a clinical-stage biopharmaceutical company focused on developing therapies for treating patients with severe liver and cardio-metabolic diseases.
Should I buy or sell 89bio stock right now?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 6 buy ratings and 1 strong buy...
What is 89bio's stock price forecast for 2022?
7 brokerages have issued 1 year price objectives for 89bio's shares. Their forecasts range from $12.00 to $60.00. On average, they expect 89bio's s...
How has 89bio's stock performed in 2022?
89bio's stock was trading at $13.07 at the beginning of 2022. Since then, ETNB shares have decreased by 73.9% and is now trading at $3.41. View th...
When is 89bio's next earnings date?
89bio is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for 89bio .
How were 89bio's earnings last quarter?
89bio, Inc. (NASDAQ:ETNB) released its quarterly earnings data on Wednesday, May, 11th. The company reported ($1.26) EPS for the quarter, beating a...
Who are 89bio's key executives?
89bio's management team includes the following people: Mr. Rohan Palekar , CEO & Director (Age 56, Pay $829.41k) ( LinkedIn Profile ) Mr. Quoc L...
Who are some of 89bio's key competitors?
Some companies that are related to 89bio include Kezar Life Sciences (KZR) , ALX Oncology (ALXO) , Alpine Immune Sciences (ALPN) , Dyne Therape...
What other stocks do shareholders of 89bio own?
Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO) , Pfizer...
When did 89bio IPO?
(ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. B...
Is 89bio stock a Buy, Sell or Hold?
89bio stock has received a consensus rating of buy. The average rating score is and is based on 18 buy ratings, 2 hold ratings, and 0 sell ratings.
What was the 52-week low for 89bio stock?
The low in the last 52 weeks of 89bio stock was 2.03. According to the current price, 89bio is 136.95% away from the 52-week low.
What was the 52-week high for 89bio stock?
The high in the last 52 weeks of 89bio stock was 22.30. According to the current price, 89bio is 12.47% away from the 52-week high.
What are analysts forecasts for 89bio stock?
The 20 analysts offering price forecasts for 89bio have a median target of 48.50, with a high estimate of 95.00 and a low estimate of 12.00. The me...
About 89bio
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
89bio (NASDAQ:ETNB) Frequently Asked Questions
8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" 89bio stock. View analyst ratings for 89bio or view top-rated stocks.
How to buy shares in 89bio
Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
Buy 89bio shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Is it a good time to buy 89bio stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
89bio share price volatility
Over the last 12 months, 89bio's shares have ranged in value from as little as $10.93 up to $28.28. A popular way to gauge a stock's volatility is its "beta".
89bio overview
89bio, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
